A cost-effectiveness analysis of vaginal co2 laser therapy compared to standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia

Topical vaginal estrogen is considered the gold standard therapy for GSM-associated dyspareunia, but early investigations of energy-based devices show promise for patients with contraindications or who are refractory to vaginal estrogen cream. While evaluating safety, efficacy and long-term outcomes for novel technologies is critically important when new technologies become available to treat unmet healthcare needs, evaluation of the costs of these new technologies compared to existing therapies is also critically important, but often understudied.

Source: American Journal of Obstetrics and Gynecology - June 16, 2020 Category: OBGYN Authors: Shannon L. Wallace, Brad ST. Martin, Kyueun Lee, Eric R. Sokol Tags: Original Research: Gynecology Source Type: research